462 completed, 141 unknown, 87 recruiting, 81 terminated. 151 Not applicable, 128 Phase 3, 123 Phase 2, 88 Phase 4, 48 Phase 1.
Follow Hypothalamic Diseases: new trials by email Literature Review of Hypothalamic Diseases trials Research Report on Hypothalamic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The AgRP and GH/IGF-1 Axis in Children Growth Hormone Deficiency | Not yet recruiting | Columbia University | 156 | 2027-06-10 | 2026-09-25 | |
| Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201 - Growth Hormone Deficiency (GHD) | Phase 3 | Not yet recruiting | Lumos Pharma | 150 | 2027-02-01 | 2026-07-08 |
| Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors SONDA - Pituitary Tumor, Visual Fields Hemianopsia | Not yet recruiting | University Medical Center Groningen | 30 | 2026-12-01 | 2026-07-23 | |
| China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation - Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor | Active not recruiting | Cheng sen | 608 | 2026-10-20 | 2026-10-21 | |
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease Norethindrone Acetate-Ethinyl Estradiol - Arginine Vasopressin Deficiency, Oxytocin Deficiency | Early Phase 1 | Recruiting | Massachusetts General Hospital | 20 | 2026-08-17 | 2026-08-21 |
| Temozolomide in Aggressive Pituitary Neuroendocrine Tumors: A Latin American Multicenter Retrospective Cohort (TMZ-LATAM) temozolamide, Temozolamide - Pituitary Neoplasms | Not yet recruiting | University of Sao Paulo General Hospital | 80 | 2026-08-01 | 2026-07-10 | |
| A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly | Phase 2 | Recruiting | Marea Therapeutics | 72 | 2026-07-23 | 2026-09-11 |
| Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures Panitumumab-IRDye800 - Meningioma, Glioblastoma | Early Phase 1 | Recruiting | Eben Rosenthal | 30 | 2026-07-07 | 2026-10-16 |
| Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels metabolic and auxological outcomes - Growth Hormone Deficiency | Not applicable | Not yet recruiting | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 300 | 2026-07-01 | 2026-05-11 |
| Direct Versus Video Laryngoscopy in Patients With Acromegaly Acromegaly, Nonfunctioning Pituitary Adenoma | Not yet recruiting | Muzaffer GENCER | 40 | 2026-07-01 | 2026-06-22 | |
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection - Adult Growth Hormone Deficiency | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 36 | 2026-06-10 | 2026-07-22 |
| GB06 Phase III Trial for Pediatric Growth Hormone Deficiency GB06, Norditropin®FlexProTM - Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children | Phase 3 | Recruiting | Kexing Biopharm Co., Ltd. | 192 | 2026-06-06 | 2026-06-10 |
| An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly Octreotide subcutaneous depot - Acromegaly | Recruiting | Camurus AB | 200 | 2026-06-05 | 2026-09-25 | |
| Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease [18F]FET PET-MRI - Cushing Disease | Not applicable | Enrolling by invitation | University Hospital, Basel, Switzerland | 43 | 2026-06-04 | 2026-07-06 |
| AI in Endoscopic Transsphenoidal Surgery Live intra-op AI analysis of endoscopic video feed, with output displayed on supplementary monitor - Pituitary Adenoma | Early Phase 1 | Not yet recruiting | University College, London | 30 | 2026-06-01 | 2026-05-05 |
| Standardized Patient Education in Pituitary Surgery Standardized Pituitary Training - Pituitary Adenoma | Not applicable | Not yet recruiting | Uludag University | 102 | 2026-06-01 | 2026-06-01 |
| Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201, Matched Placebo (Capsules) - Growth Hormone Deficiency (GHD) | Phase 3 | Recruiting | Lumos Pharma | 150 | 2026-05-20 | 2026-10-19 |
| Combination Osilodrostat and Cabergoline in Cushing's Disease osilodrostat, osilodrostat and cabergoline - Cushing Disease Due to Increased ACTH Secretion | Phase 4 | Enrolling by invitation | University of Basrah | 50 | 2026-05-11 | 2026-05-22 |
Showing 20 of 843. Sign in to see all of them.
Dwarfism, Pituitary (252) · Acromegaly (200) · Pituitary Neoplasms (192) · Pituitary Diseases (74) · Pituitary ACTH Hypersecretion (61) · Hypopituitarism (46) · Inappropriate ADH Syndrome (41) · Hyperprolactinemia (39) · Hyponatremia (32) · Prolactinoma (28) · Cushing Syndrome (25) · Obesity (20) · Brain Neoplasms (19) · Insulin Resistance (19) · Bardet-Biedl Syndrome (18)
Central Nervous System Diseases (843) · Nervous System Diseases (842) · Brain Diseases (841) · Endocrine System Diseases (808) · Pituitary Diseases (745) · Musculoskeletal Diseases (459) · Bone Diseases (453) · Bone Diseases, Endocrine (447) · Hyperpituitarism (294) · Bone Diseases, Developmental (264) · Hypopituitarism (243) · Dwarfism (238) · Neoplasms (236) · Neoplasms by Site (227)
Human Growth Hormone (83) · Growth Hormone (46) · Octreotide (29) · lanreotide (21) · Cabergoline (20) · pasireotide (20) · pegvisomant (20) · Blood Specimen Collection (11) · Tolvaptan (11) · somapacitan (11) · Injections (8) · Growth Hormone-Releasing Hormone (6) · Sodium Chloride (6) · Surveys and Questionnaires (6) · Absorptiometry, Photon (5)
Ipsen (35) · Novo Nordisk A/S (27) · Pfizer (26) · Novartis Pharmaceuticals (24) · University of Aarhus (18) · Federico II University (17) · Columbia University (16) · Changchun GeneScience Pharmaceutical Co., Ltd. (15) · University Hospital, Basel, Switzerland (15) · Cedars-Sinai Medical Center (14) · Massachusetts General Hospital (13) · Huashan Hospital (11) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (9) · Merck KGaA, Darmstadt, Germany (9) · Corcept Therapeutics (8)
United States (282) · Italy (112) · France (103) · Germany (97) · United Kingdom (80) · China (74) · Spain (63) · Poland (51) · Denmark (50) · Hungary (45) · Netherlands (44) · Belgium (40) · Brazil (37) · Canada (37) · Turkey (Türkiye) (35)
Shlomo Melmed, MD (5) · Pamela U. Freda, MD (4) · Prashant Chittiboina, M.D. (4) · Will Charlton, MD (4) · Andrew Little, MD (3) · Anna Aulinas, MD PhD (3)
PMID 17259801, PMID 17984237, PMID 36380045, PMID 10690849, PMID 12641619, PMID 14769829, PMID 15613435, PMID 15827109, PMID 16449332, PMID 16487447, PMID 16537687, PMID 17105757, PMID 18395480, PMID 18445662, PMID 19556464, PMID 22027579, PMID 22154461, PMID 22508317, PMID 22788856, PMID 23658497, PMID 24291224, PMID 25013998, PMID 25151571, PMID 25209242, PMID 26507877, PMID 27405306, PMID 27864853, PMID 28566441, PMID 29343557, PMID 29395172, PMID 29671202, PMID 31062234, PMID 31305924, PMID 31972476, PMID 33571362, PMID 33709288, PMID 33754315, PMID 34173129, PMID 35058882, PMID 35954244, PMID 36792844, PMID 36947589, PMID 40418492, PMID 40919719, PMID 41052284, PMID 41701620, PMID 9808008, PMID 10022400, PMID 10199767, PMID 10199774
2018 (9), 2004 (6), 2014 (5), 2015 (5), 2008 (4), 2009 (4), 2016 (4), 2017 (4), 2019 (4), 2005 (2), 2023 (2), 2025 (2), R01DK110771 (2), R01HL085268 (2), K23MH085005 (1)